Combining Immunotherapies with Standard Therapies in the Treatment of Cancer

Jonathan M. Pitt, Dalil Hannani, Marie Vétizou, Laurence Zitvogel

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    1 Citation (Scopus)

    Abstract

    The host immune response against tumors has been proven to be a critical component following cancer therapy that can determine cancer control and patient survival. This understanding has given rise to immunotherapy, which has revolutionized the clinical treatment of cancer by harnessing a patient's immune system to target tumors. Although the current arsenal of immunotherapies shows clinical efficacy, this is often not true for all patients. It is thought that approaches that combine standard cancer treatments with immunotherapy may improve overall efficacy by adapting the tumor microenvironment to a more immunogenic state, and by providing a multifaceted attack against which tumors have less likelihood of escape. In this article, we review how immunotherapies may be combined successfully with clinically available chemotherapies, targeted therapies, or radiotherapy for a synergistic control of tumors.

    Original languageEnglish
    Title of host publicationImmunity to Pathogens and Tumors
    PublisherElsevier Inc.
    Pages569-580
    Number of pages12
    Volume4
    ISBN (Print)9780080921525
    DOIs
    Publication statusPublished - 27 Apr 2016

    Keywords

    • Antitumor immune response
    • Cancer
    • Chemotherapy
    • Dendritic cell
    • Immunochemotherapy
    • Immunogenic cell death
    • Immunotherapy
    • Radiotherapy
    • T cell
    • Targeted therapy
    • Tumor immunoediting
    • Tumor microenvironment

    Cite this